Fernandez-L Africa, Garrido-Martin Eva M, Sanz-Rodriguez Francisco, Pericacho Miguel, Rodriguez-Barbero Alicia, Eleno Nelida, Lopez-Novoa Jose M, Düwell Anette, Vega Miguel A, Bernabeu Carmelo, Botella Luisa M
Centro de Investigaciones Biológicas, CSIC, Madrid, Spain, 2 Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Hum Mol Genet. 2007 Jul 1;16(13):1515-33. doi: 10.1093/hmg/ddm069. Epub 2007 Apr 9.
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is an autosomal dominant vascular disorder characterized by telangiectases and internal arteriovenous malformations. It is caused by mutations in elements of the transforming growth factor-beta (TGF-beta) receptor complex: endoglin, a co-receptor, responsible for HHT1, or ALK1 (activin receptor-like kinase 1), a type I receptor leading to HHT2. Recently, we have established cultures of HHT endothelial cells, primary targets of the disease. These cells showed deficient TGF-beta signaling and angiogenesis, representing a useful human model to study the molecular mechanism of this disease. To understand the pathogenic mechanism underlying HHT, we have used total RNA probes to compare HHT versus non-HHT cells by expression microarrays. This work represents a systematic study to identify target genes affected in HHT cells. Given the similarity of symptoms in HHT1 and HHT2, special interest has been put on the identification of common targets for both HHT types. As a result, 277 downregulated and 63 upregulated genes were identified in HHT versus control cells. These genes are involved in biological processes relevant to the HHT pathology, such as angiogenesis, cytoskeleton, cell migration, proliferation and NO synthesis. The type of misregulated genes found in HHT endothelial cells lead us to propose a model of HHT pathogenesis, opening new perspectives to understand this disorder. Moreover, as the disease is originated by mutations in proteins of the TGF-beta receptor complex, these results may be useful to find out targets of the TGF-beta pathway in endothelium.
遗传性出血性毛细血管扩张症(HHT)或奥斯勒-韦伯-伦杜综合征是一种常染色体显性血管疾病,其特征为毛细血管扩张和体内动静脉畸形。它是由转化生长因子-β(TGF-β)受体复合物成分的突变引起的:作为共受体的内皮糖蛋白导致HHT1,而I型受体激活素受体样激酶1(ALK1)导致HHT2。最近,我们建立了HHT内皮细胞培养体系,内皮细胞是该疾病的主要靶细胞。这些细胞显示出TGF-β信号传导和血管生成缺陷,是研究该疾病分子机制的有用人体模型。为了了解HHT的致病机制,我们使用总RNA探针通过表达微阵列比较HHT细胞与非HHT细胞。这项工作是一项系统性研究,旨在鉴定HHT细胞中受影响的靶基因。鉴于HHT1和HHT2症状相似,人们特别关注鉴定两种HHT类型的共同靶标。结果,在HHT细胞与对照细胞中鉴定出277个下调基因和63个上调基因。这些基因参与了与HHT病理学相关的生物学过程,如血管生成、细胞骨架、细胞迁移、增殖和一氧化氮合成。在HHT内皮细胞中发现的失调基因类型使我们提出了HHT发病机制模型,为理解这种疾病开辟了新的视角。此外,由于该疾病是由TGF-β受体复合物蛋白的突变引起的,这些结果可能有助于找出内皮细胞中TGF-β信号通路的靶标。